Rutgers Innovation Ventures has executed an exclusive license between Rutgers, The State University of New Jersey and the startup RenewCO2.
Our objective is to optimize an inhibitor of the malaria-causing parasite, Plasmodium. We will use structure-guided design to optimize the molecule’s potency against its target kinase. The resulting medicinal chemistry program will yield highly potent and selective inhibitors of Plasmodium suitable for further development of an anti-malarial drug.
Development of an alternative separation technology based on adsorptive separation which will significantly reduce the energy input and lower the cost associated with the generation of polymer-grade propylene.
This technology is a virus-based gene therapy for the treatment of spinal cord injury (SCI). The treatment dramatically improves locomotor behavior in a mouse model of SCI by promoting the generation of new neurons for the re-establishment of damaged neural circuits and reducing the glial scar formation at the lesion site.
Development of small molecules inhibitors of Keap1-Nrf2 PPI as chemopreventive and therapeutic agents for the treatment of ulcerative colitis
By playing a 5-minute computer game, we designed a computerized system that can screen for clinical depression and predict response to antidepressants in advance with a 95% accuracy. This system builds on research in cognitive neuroscience, applied mathematics, and machine learning.